naa a22 4500 510740545 CHVBK 20180411083026.0 cr unu---uuuuu 180411e20130901xx s 000 0 eng 10.1007/s11845-013-0918-x doi (NATIONALLICENCE)springer-10.1007/s11845-013-0918-x Stereotactic radiosurgery for the treatment of brain metastases; results from a single institution experience [Elektronische Daten] [D. Burke, C. Mascott, L. Rock, S. Callinan, A. Mihai, P. Thirion, J. Armstrong] Background: Stereotactic radiosurgery is frequently used for the treatment of brain metastases. This study provides a retrospective evaluation of patients with secondary lesions of the brain treated with stereotactic radiosurgery (SRS) at our institution. Aims: To provide outcome data from a single institutional experience with SRS and identify any significant prognostic factors in the cohort. Methods: Sixty-seven patients received first time SRS to 86 intracranial metastases between 2007 and 2010. Sixteen patients were excluded from this study due to the absence of post-treatment neuroimaging, resulting in 51 patients with 64 treated lesions. Of these patients, 37 (72.5%) received SRS electively, while 14 (27.5%) received salvage SRS after brain metastasis progression following whole brain radiotherapy. Results: Median survival for the entire group was 15months from the date of radiosurgery. Patients without active extracranial disease had statistically significant survival time than those with active extracranial disease (P=0.03). 45 (70.3%) lesions achieved local tumour control in 34 patients (66.7%) with a mean follow-up period of 10.7months (range 1.7-33.6months, 95% confidence interval 6.6-9.8months). Conclusions: The results reported in this study equate to those reported in other series consolidating SRS as an effective treatment option with few serious complications. Developments in systemic disease control will see further improvements in overall survival. Royal Academy of Medicine in Ireland, 2013 Stereotactic radiosurgery nationallicence Brain metastases nationallicence Linear accelerator nationallicence Varian trilogy nationallicence Burke D. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Mascott C. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Rock L. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Callinan S. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Mihai A. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Thirion P. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Armstrong J. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut Irish Journal of Medical Science Springer-Verlag 182/3(2013-09-01), 481-485 0021-1265 182:3<481 2013 182 11845 https://doi.org/10.1007/s11845-013-0918-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11845-013-0918-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Burke D. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Mascott C. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Rock L. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Callinan S. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Mihai A. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Thirion P. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 700 1- Armstrong J. UPMC Beacon Cancer Centre, UPMC Beacon Hospital, Sandyford, 18, Dublin, Ireland aut NATIONALLICENCE 773 0- Irish Journal of Medical Science Springer-Verlag 182/3(2013-09-01), 481-485 0021-1265 182:3<481 2013 182 11845 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer